Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 176

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease

Open access
Olivier, Kenneth N., Shaw, Pamela A., Glaser, Tanya S., Bhattacharyya, Darshana, Fleshner, Michelle, Brewer, Carmen C., Zalewski, Christopher K., Folio, Les R., Siegelman, Jenifer R., Shallom, Shamira, Park, In Kwon, Sampaio, Elizabeth P., Zelazny, Adrian M., Holland, Steven M., Prevots, D. Rebecca·2014·Annals of the American Thoracic Society

Abstract

Rationale: Treatment of pulmonary nontuberculous mycobacteria, especially Mycobacterium abscessus, requires prolonged, multidrug regimens with high toxicity and suboptimal efficacy. Options for refractory disease are limited. Objectives: We reviewed the efficacy and toxicity of inhaled amikacin in patients with treatment-refractory nontuberculous mycobacterial lung disease. Methods: Records were queried to identify patients who had inhaled amikacin added to failing regimens. Lower airway microbiology, symptoms, and computed tomography scan changes were assessed together with reported toxicity. Measurements and Main Results: The majority (80%) of the 20 patients who met entry criteria were women; all had bronchiectasis, two had cystic fibrosis and one had primary ciliary dyskinesia. At initiation of inhaled amikacin, 15 were culture positive for M. abscessus and 5 for Mycobacterium avium complex and had received a median (range) of 60 (6, 190) months of mycobacterial treatment. Patients were followed for a median of 19 (1, 50) months. Eight (40%) patients had at least one negative culture and 5 (25%) had persistently negative cultures. A decrease in smear quantity was noted in 9 of 20 (45%) and in mycobacterial culture growth for 10 of 19 (53%). Symptom scores improved in nine (45%), were unchanged in seven (35%), and worsened in four (20%). Improvement on computed tomography scans was noted in 6 (30%), unchanged in 3 (15%), and worsened in 11 (55%). Seven (35%) stopped amikacin due to: ototoxicity in two (10%), hemoptysis in two (10%), and nephrotoxicity, persistent dysphonia, and vertigo in one each. Conclusions: In some patients with treatment-refractory pulmonary nontuberculous mycobacterial disease, the addition of inhaled amikacin was associated with microbiologic and/or symptomatic improvement; however, toxicity was common. Prospective evaluation of inhaled amikacin for mycobacterial disease is warranted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1513/annalsats.201307-231oc

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 176

Metadata

Authors
Olivier, K. N., Shaw, P. A., Glaser, T. S., Bhattacharyya, D., Fleshner, M., Brewer, C. C., Zalewski, C. K., Folio, L. R., Siegelman, J. R., Shallom, S., Park, I. K., Sampaio, E. P., Zelazny, A. M., Holland, S. M., & Prevots, D. R.
Venue
Annals of the American Thoracic Society
Published
2014-01-01
Volume
11
Issue
1
Pages
30-35
ISSN
  • 2325-6621 (ISSN-L)
  • 2329-6933
OpenAlex
W2118287340
Cited by
176
References
1
FWCI
15.73
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease. https://app.cochat.ai/papers/10.1513/annalsats.201307-231oc
The paper
Olivier, K. N., Shaw, P. A., Glaser, T. S., Bhattacharyya, D., Fleshner, M., Brewer, C. C., Zalewski, C. K., Folio, L. R., Siegelman, J. R., Shallom, S., Park, I. K., Sampaio, E. P., Zelazny, A. M., Holland, S. M., & Prevots, D. R. (2014). Inhaled Amikacin for Treatment of Refractory Pulmonary Nontuberculous Mycobacterial Disease. Annals of the American Thoracic Society. https://doi.org/10.1513/annalsats.201307-231oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.